Abstract: Compositions and methods are provided in which magnesium, copper, zinc, and strontium are provided to enhance osteogenesis, improve bone growth, and/or improve bone density. Magnesium, copper, zinc, and strontium are provided in a defined molar ratio providing synergistic effects that permit the use of small amounts of individual metal species, and without the need for supplemental calcium.

Abstract: The present disclosure provides pharmaceutical combinations of orally administered docetaxel and a P-gp inhibitor. The pharmaceutical combinations are suitable for the treatment of cancer in a subject and for reducing or preventing toxicity, hypersensitivity-type infusion reactions, and other negative outcomes resulting from or associated with intravenously administered docetaxel (e.g., Taxotere® or docetaxel formulated with polysorbate 80) therapy in a subject suffering from cancer.

Abstract: A pharmaceutical composition comprises a taxane (e.g., paclitaxel, docetaxel, cabazitaxel, larotaxel, ortataxel, and/or tesetaxel) in a mixture of first and second surfactants. The absorption of the taxane is increased from the pharmaceutical composition is greater than the sum of the absorption of docetaxel from either the first or the second surfactant. The increase in absorption is especially enhanced when the ratio of the first surfactant to the second surfactant in the pharmaceutical composition is between 60:40 and 85:15 by weight, and the total surfactant weight does not exceed 98% of the total weight. Polysorbate 80, polysorbate 20, and caprylocaproyl polyoxylglycerides serve as suitable first surfactants, and polysorbate 80 or polyethyoxylated castor oil serve as suitable second surfactants. The stability of the pharmaceutical composition may be enhanced by further including a stabilizer (e.g., citric acid and/or ascorbic acid).

Abstract: AM580 and structurally related compounds have been found to be useful in treating infection by a wide range of RNA and DNA viruses, and also in reducing associated inflammation. This activity is independent of RAR-? signaling, and is not a result of activation of the hosts innate immune response.

Abstract: Miltefosine is utilized to enhance immune response to vaccination, for example an influenza and/or coronavirus vaccination. The inventive subject matter also provides compositions and methods for enhancing viral yield in cultured cells, by application of a cannabinoid receptor agonist (such as methanandamide) to such cells. Such enhanced viral yield can be used to enhance virus production for purposes of vaccine formulation and/or to improve sensitivity of cell-based virus assays.

Abstract: A phototherapy device, a kit containing such a phototherapy device, and a method for treating a patient with a phototherapy device, the phototherapy device containing a housing, an emission portion, and a light tube, the housing containing a light source that emits light at a wavelength of from about 400 nm to about 550 nm, and may contain a light shield proximal to the light source, the emission portion being distal form the housing and connected thereto via a light tube which contains an optical fibre, and a mesh that may enclose the optical fibre and may allow a limited amount of light to leak from the optical fibre to the outside environment.

Abstract: The application pertains to methods of treating and/or preventing actinic keratosis, comprising administering a therapeutically effective amount of KX-01, to a subject in need thereof.

Abstract: The present disclosure provides pharmaceutical combinations of orally administered irinotecan and a P-gp inhibitor. The pharmaceutical combinations are suitable for the treatment of cancer in a subject and for reducing or preventing toxicity, hypersensitivity-type infusion reactions, and other negative outcomes resulting from or associated with intravenously administered irinotecan (e.g., Camptosar®) therapy in a subject suffering from cancer.

Abstract: The present disclosure provides pharmaceutical combinations of orally administered docetaxel and a P-gp inhibitor. The pharmaceutical combinations are suitable for the treatment of cancer in a subject and for reducing or preventing toxicity, hypersensitivity-type infusion reactions, and other negative outcomes resulting from or associated with intravenously administered docetaxel (e.g., Taxotere® or docetaxel formulated with polysorbate 80) therapy in a subject suffering from cancer.

Abstract: Compositions and methods are described in which the topical application of a toll-like receptor 7 agonist or a toll-like receptor 9 agonist at or near a subdermal vaccination site provides an enhanced response to the vaccination. The enhanced response can be an elevated antibody titer relative to an untreated but vaccinated subject, and/or development of cross-species immunity to species not present in the vaccinating composition.

Abstract: A galactose rapid detection system has a galactose composition including a galactose, a buffer solution and an 0-99% antioxidant, which enters a human body after metabolism and produces a biological sample; a test strip or a filter paper, comprising an enzyme, the enzyme would react with the biological sample producing a electrochemical information ;a meter including a power supply unit for providing a signal; a connector for receiving the signal provided by the power supply unit, transmitting the signal to the test strip or the filter paper, wherein the signal reacting with the electrochemical information produce a corresponding response signal, and the connector transmit the corresponding response signal to the meter; a calculation unit for calculating the corresponding response signal; an A/D convertor for receiving the corresponding response signal from the calculation unit, transforming the corresponding response signal into a digital reaction signal calculated by the calculation unit; and a processor fo

Abstract: The application pertains to methods of treating and/or preventing actinic keratosis, comprising administering a therapeutically effective amount of KX-01, to a subject in need thereof.

Abstract: Compositions and methods are described in which the topical application of a toll-like receptor 7 agonist or a toll-like receptor 9 agonist at or near a subdermal vaccination site provides an enhanced response to the vaccination. The enhanced response can be an elevated antibody titer relative to an untreated but vaccinated subject, and/or development of cross-species immunity to species not present in the vaccinating composition.

Abstract: Methods are provided for treating an individual with a pharmaceutical preparation that includes a recombinant IL-11 PEGylated at equimolar to low molar excess of PEG to achieve a highly pure monoconjugate preparation, which provides improved half-life in serum while having desirable therapeutic activity and presenting fewer side-effects. Most preferably, the IL-11 is an N-terminally truncated human or humanized IL-11 and has a 20 Kd or 40 Kd branched PEG moiety, Y- or comb-shaped in particular, coupled to the N-terminal amino group. Such compounds are characterized by substantially increased stability in serum and sustained biological activity while exhibiting significantly reduced plasma expansion.

Abstract: Compositions are presented that include a recombinant IL-11 PEGylated at equimolar to low molar excess of PEG to achieve a highly pure monoconjugate preparation, which provides improved half-life in serum while having desirable therapeutic activity and presenting fewer side-effects. Most preferably, the IL-11 is an N-terminally truncated human or humanized IL-11 and has a 20 Kd or 40 Kd branched PEG moiety, Y- or comb-shaped in particular, coupled to the N-terminal amino group. Such compounds are characterized by substantially increased stability in serum and sustained biological activity while exhibiting significantly reduced plasma expansion.

Abstract: Enteroviruses, such as EV-A71, have been found to utilize hWARS as a cell surface receptor, with expression ofhWARS rendering cells susceptible to enteroviral infection. Reduction in hWARS cell surface activity reduces susceptibility to enteroviral infection and provides a mode for treatment or prevention of enteroviral infection and its sequelae. Similarly, expression of hWARS in cultured cells and animal models provides models for understanding enteroviral disease mechanisms and the development of vaccines and/or pharmaceuticals for preventing or treating enteroviral disease.

Abstract: Compositions and methods are described that provide prognostic determination of the severity of influenza infection based on the PDE3A status of an individual. Impaired PDE3A function is associated with severe symptoms on contracting influenza. Specific SNP mutations are identified that are associated with impaired PDE3A function, and primers and kits are provided that permit identification of these SNPs. Such information can also be combined with other patient data.

Abstract: Devices and methods that utilize an occlusive dressing in combination with a topical pharmaceutical agent to enhance vaccine efficacy are described. The occlusive dressing delivers a defined dose of a topical pharmaceutical agent that enhances immune system reactivity to a vaccine to the site of vaccination, and provides a barrier that maintains a layer of the topical pharmaceutical agent on the skin for a desired period to time while also providing a port through which an immunizing composition can be administered. In some embodiments the occlusive dressing includes a wound dressing for covering the injection site following vaccination.

Abstract: The application pertains to pharmaceutical combinations of orally administered paclitaxel and a P-gp inhibitor. The pharmaceutical combinations are suitable for the treatment of an angiosarcoma in a subject and for reducing or preventing toxicity, hypersensitivity-type infusion reactions, and other negative outcomes resulting from or associated with intravenously administered paclitaxel (e.g., Taxol® or paclitaxel formulated with Cremophor®) therapy in a subject suffering from an angiosarcoma.